Valuing the EQ-5D-Y Using a Discrete Choice Experiment: Do Adult and Adolesce...Office of Health Economics
Slides from a presentation OHE's Koonal Shah gave at the PROMs research conference on June 20th, 2018. The subject of the presentation was valuing the EQ-5D-Y using a discrete choice experiment: do adult and adolescent preferences differ?
Unprecedented medical advances in cancer treatments are accompanied with huge financial challenges. Outcome-based payments have been proposed as a potential way to foster earlier access, tackle uncertainty, and address the financial challenge. But payments based on what outcomes? We conducted a literature review exploring what outcomes “matter most” in cancer.
Author(s) and affiliation(s): Amanda Cole, OHE Patricia Cubi-Molla, OHE Paula Lorgelly, OHE Jon Sussex, RAND Europe Jack Pollard, RAND Europe Miaoqing Yang, RAND Europe Richard Sullivan, King's College London
Conference/meeting: PROMS Research Conference 2018
Location: University of Birmingham
Date: 20/06/2018
Valuing the EQ-5D-Y Using a Discrete Choice Experiment: Do Adult and Adolesce...Office of Health Economics
Slides from a presentation OHE's Koonal Shah gave at the PROMs research conference on June 20th, 2018. The subject of the presentation was valuing the EQ-5D-Y using a discrete choice experiment: do adult and adolescent preferences differ?
Unprecedented medical advances in cancer treatments are accompanied with huge financial challenges. Outcome-based payments have been proposed as a potential way to foster earlier access, tackle uncertainty, and address the financial challenge. But payments based on what outcomes? We conducted a literature review exploring what outcomes “matter most” in cancer.
Author(s) and affiliation(s): Amanda Cole, OHE Patricia Cubi-Molla, OHE Paula Lorgelly, OHE Jon Sussex, RAND Europe Jack Pollard, RAND Europe Miaoqing Yang, RAND Europe Richard Sullivan, King's College London
Conference/meeting: PROMS Research Conference 2018
Location: University of Birmingham
Date: 20/06/2018
CLINICAL GOVERNANCE SYSTEMS - AS A TOOL FOR IMPROVING PATIENT SAFETY Ruby Med Plus
This essay explores how Clinical governance as a process is interpreted,
understood and practiced for improving the quality of patient care and Patient
safety.
Specific Objectives-
1. To give an overview of corporate governance and Clinical governance and
to focus on Definition, principles, need, components, key features and
benefits of Clinical governance.
2. To Understand the principles and Pre-requisites of Governance and
clinical governance.
3. To comprehend Power Culture, Quality Assurance, Clinical Audit, and
Clinical Governance.
4. To analyse decision making, safety culture, Integrated pathways,
informed consent, right clinical information, Acrediation and Clinical
Governance.
Implementing Clinical Governance in an AOD treatment serviceUniting ReGen
2017 VAADA Conference presentation - Venetia Brissenden considers ReGen's experience of developing a fully integrated Clinical Governance system and options for other service providers.
As populations increase, health resources shrink, and access and quality of life equity differences widen, the clarion call for innovation in healthcare is growing louder around the world. Both international groups such as the World Health Organization and national groups, e.g., ministry of health, continue to set aggressive goals and billions have been spent to design and implement global health innovations.
Many global health innovations (GHI) have set high goals but had limited success in implementation or never scaled to serve a wider population. The barriers to implementing global healthcare innovations include policies or political priorities, lack of commitment, limited infrastructure, and limited healthcare staff. Some health entrepreneurs have overcome such barriers; Yet other, well intentioned and planned GHI have not met expectations.
Although some articles provide suggestions for avoiding, overcoming and addressing these barriers, few offer new models for global health innovation. In this research, we offer a four component model that considers the adoptive community, implementation team, the delivery strategy and the delivery approach as key enablers for successful GHI. This model is supported by the literature and in-depth case studies in Uganda, Ghana, Mozambique, and Haiti.
Needs Analysis of Primary Care Physicians and Other Providers in Terms of Obe...Clinical Tools, Inc
Tanner, B. Needs Analysis of Primary Care Physicians and
Other Providers in Terms of Obesity Training. Poster
presented Overcoming Obesity: Diagnose. Personalize.
Treat. Conference of the American Society of Bariatric
Physicians, September 12, 2014 Austin Texas.
Dr. Richard A May, MD, PhD, D.H.Sc. Certificate Antimicrobial Stewardship Module 9 - The CMS Core Performance Measures for Community Acquired Pneumonia - CAP - 87297 13912-1
Clinical Governance Presentation by Michael Gorton AM - 21 July 2016Russell_Kennedy
Clinical governance in the health sector. This presentation covers the issues of liability, accountability, risk management and compliance that all health organisations must address.
CLINICAL GOVERNANCE SYSTEMS - AS A TOOL FOR IMPROVING PATIENT SAFETY Ruby Med Plus
This essay explores how Clinical governance as a process is interpreted,
understood and practiced for improving the quality of patient care and Patient
safety.
Specific Objectives-
1. To give an overview of corporate governance and Clinical governance and
to focus on Definition, principles, need, components, key features and
benefits of Clinical governance.
2. To Understand the principles and Pre-requisites of Governance and
clinical governance.
3. To comprehend Power Culture, Quality Assurance, Clinical Audit, and
Clinical Governance.
4. To analyse decision making, safety culture, Integrated pathways,
informed consent, right clinical information, Acrediation and Clinical
Governance.
Implementing Clinical Governance in an AOD treatment serviceUniting ReGen
2017 VAADA Conference presentation - Venetia Brissenden considers ReGen's experience of developing a fully integrated Clinical Governance system and options for other service providers.
As populations increase, health resources shrink, and access and quality of life equity differences widen, the clarion call for innovation in healthcare is growing louder around the world. Both international groups such as the World Health Organization and national groups, e.g., ministry of health, continue to set aggressive goals and billions have been spent to design and implement global health innovations.
Many global health innovations (GHI) have set high goals but had limited success in implementation or never scaled to serve a wider population. The barriers to implementing global healthcare innovations include policies or political priorities, lack of commitment, limited infrastructure, and limited healthcare staff. Some health entrepreneurs have overcome such barriers; Yet other, well intentioned and planned GHI have not met expectations.
Although some articles provide suggestions for avoiding, overcoming and addressing these barriers, few offer new models for global health innovation. In this research, we offer a four component model that considers the adoptive community, implementation team, the delivery strategy and the delivery approach as key enablers for successful GHI. This model is supported by the literature and in-depth case studies in Uganda, Ghana, Mozambique, and Haiti.
Needs Analysis of Primary Care Physicians and Other Providers in Terms of Obe...Clinical Tools, Inc
Tanner, B. Needs Analysis of Primary Care Physicians and
Other Providers in Terms of Obesity Training. Poster
presented Overcoming Obesity: Diagnose. Personalize.
Treat. Conference of the American Society of Bariatric
Physicians, September 12, 2014 Austin Texas.
Dr. Richard A May, MD, PhD, D.H.Sc. Certificate Antimicrobial Stewardship Module 9 - The CMS Core Performance Measures for Community Acquired Pneumonia - CAP - 87297 13912-1
Clinical Governance Presentation by Michael Gorton AM - 21 July 2016Russell_Kennedy
Clinical governance in the health sector. This presentation covers the issues of liability, accountability, risk management and compliance that all health organisations must address.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
**Rosenfeld - Consumers and Guidelines: Lessons Learned, Opportunities Ahead
1. Consumers & Guidelines IOM Report on Guideline Standards Richard M. Rosenfeld, MD, MPH Professor and Chairman of Otolaryngology, SUNY Downstate Chair, Guideline Development Task Force, AAO-HNS Chair, G-I-N North America Steering Group
2.
3. AAO-HNS Adult Sinusitis Guideline Rhinosinusitis Guideline Panel Patricia Hudgins (head and neck radiology) ASHNR Dickson Cheung (emergency medicine) ACEP Richard Shiffman (methodology) AAP John Mitchell (chest physicians) ACCP Theodore Ganiats, Martin Mahoney (family practice) AAFP Daniel Hamilos, Robert Nathan (allergy and immunology) AAAAI Helene Krouse (advance practice nursing) SOHN Steven Eisenberg, Larry Lee (United Healthcare), Andrea Gelzer (CIGNA) Insurance David Andes (infectious disease) IDSA Richard Rosenfeld (chair), Neil Bhattacharyya, Tim Smith, Bradley Marple (ARS, SAHP), Richard Haydon III (AAOA, SAHP), David Witsell AAO-HNS Participants Group
4. Begin with the End in Mind Covey S. The 7 Habits of Highly Effective People. Fireside Press, 1989 Habit #2, Stephen Covey Consumers
5.
6. What do Consumers contribute to GDGs? Consumer Involvement in Guidelines What are the Possibilities? Passion Perspective Skepticism Respect for harms Patient education Shared decisions
7.
8. What Are Clinical Practice Guidelines? Guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Institute of Medicine 1990 www.iom.edu Guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options. Institute of Medicine 2011 New definition clearly distinguishes “Clinical Practice Guidelines” from other forms of clinical guidance derived from widely disparate development processes (e.g., consensus statements, appropriate use criteria, practice paramaters)
14. An Educated Consumer…Can be the Best Member of a Guideline Development Group Thank You for Your Kind Attention! Richard M. Rosenfeld, MD, MPH – richrosenfeld@msn.com